Treating neurogenic detrusor overactivity in order to manage autonomic dysreflexia - A systematic review.

Auton NeurosciJul 8, 2026 (epub)
Clinical ResearchUrologyNeurology

Ba Thien Le, Pierre Denys, Charles Joussain

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the effects of treating neurogenic detrusor overactivity (NDO) on autonomic dysreflexia (AD) in patients with spinal cord injury (SCI). Among five included studies, treatment with botulinum toxin (BTX) and fesoterodine showed improved urodynamic parameters and reduced severity of AD. Notably, one study with 12 patients using fesoterodine indicated positive outcomes.

Key findings

  • Treatment with BTX and fesoterodine improved urodynamic parameters in patients with SCI.
  • A decrease in severity of autonomic dysreflexia was observed during urodynamic studies.
  • Improvements in AD-HR-QoL and I-QoL scores were demonstrated in treated patients.

Why it matters

Understanding the relationship between NDO treatment and AD management is crucial for improving patient outcomes in those with spinal cord injuries. Effective management of AD can significantly enhance quality of life and reduce the risk of life-threatening complications.

Source

PubMed · PMID 42430939

Published in Auton Neurosci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.